GT Biopharma, Inc. (GTBP) Operating cash flow 2016–2025
GT Biopharma, Inc. (GTBP) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$12.9MFY2025 · since FY2016: -$1.9M → -$12.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.9M | -0.1% |
| FY2024 | -$12.9M | -45.8% |
| FY2023 | -$8.9M | +41.8% |
| FY2022 | -$15.2M | +2.5% |
| FY2021 | -$15.6M | -114.9% |
| FY2020 | -$7.3M | -98.5% |
| FY2019 | -$3.7M | +65.7% |
| FY2018 | -$10.7M | -96.6% |
| FY2017 | -$5.4M | -181.3% |
| FY2016 | -$1.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More GTBP financial trends
GTBP RevenueGTBP Net incomeGTBP Net marginGTBP Gross profitGTBP Gross marginGTBP Operating incomeGTBP Operating marginGTBP Free cash flowGTBP Capital expendituresGTBP Return on equityGTBP Stock buybacksGTBP Dividends paidGTBP Total assetsGTBP Total liabilitiesGTBP Shareholders’ equityGTBP overview →